Standout Papers
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial (2010)
- Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial (2010)
Citation Impact
Citing Papers
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
2012
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
2013
Combining a PI3K Inhibitor with a PARP Inhibitor Provides an Effective Therapy for BRCA1-Related Breast Cancer
2012
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Targeted therapies for breast cancer
2011
Hypoxia-inducible factors and RAB22A mediate formation of microvesicles that stimulate breast cancer invasion and metastasis
2014 StandoutNobel
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Triple negative breast cancer: unmet medical needs
2010
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
2011 Standout
Mutational landscape and significance across 12 major cancer types
2013 StandoutNature
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
Triple-Negative Breast Cancer: An Unmet Medical Need
2011
Triple-Negative Breast Cancer
2010 Standout
Pancreatic cancer
2004 Standout
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial
2014
Pretreatment with Prasugrel in Non–ST-Segment Elevation Acute Coronary Syndromes
2013
Clopidogrel with or without Omeprazole in Coronary Artery Disease
2010 Standout
A view on drug resistance in cancer
2019 StandoutNature
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
2015
BRCAness revisited
2016
PARP inhibitor combination therapy
2016
Nucleotide signalling during inflammation
2014 StandoutNature
Safety, Tolerability, and Initial Efficacy of AZD6140, the First Reversible Oral Adenosine Diphosphate Receptor Antagonist, Compared With Clopidogrel, in Patients With Non–ST-Segment Elevation Acute Coronary Syndrome
2007
Ovarian cancer
2014 Standout
Appraising iniparib, the PARP inhibitor that never was—what must we learn?
2013
Variability in Individual Responsiveness to Clopidogrel
2007
A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
2013
Cytochrome P-450 Polymorphisms and Response to Clopidogrel
2008 Standout
Drug development and clinical trials—the path to an approved cancer drug
2012
Olaparib: First Global Approval
2015
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
New Antithrombotic Drugs
2012
Emergency Hospitalizations for Adverse Drug Events in Older Americans
2011 Standout
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes
2009 Standout
Cediranib, a pan-VEGFR inhibitor, and olaparib, a PARP inhibitor, in combination therapy for high grade serous ovarian cancer
2016
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
Incidence of Dyspnea and Assessment of Cardiac and Pulmonary Function in Patients With Stable Coronary Artery Disease Receiving Ticagrelor, Clopidogrel, or Placebo in the ONSET/OFFSET Study
2010
Combination cediranib and olaparib versus olaparib alone for women with recurrent platinum-sensitive ovarian cancer: a randomised phase 2 study
2014
Ticagrelor
2011
Integrated genomic characterization of endometrial carcinoma
2013 StandoutNature
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
2016 Standout
Raise standards for preclinical cancer research
2012 StandoutNature
Evaluation of Factors Related to Late Recurrence - Later than 10 Years after the Initial Treatment - in Primary Breast Cancer
2013 Standout
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
2013
Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes Undergoing Coronary Artery Bypass Surgery
2010
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
Ticagrelor vs. clopidogrel in patients with non-ST-elevation acute coronary syndrome with or without revascularization: results from the PLATO trial
2014
Death by releasing the breaks: CHK1 inhibitors as cancer therapeutics
2010
Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: Rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial
2009
Effect of antiplatelet therapy on inflammatory markers in atherothrombotic patients
2009
Synthetic lethality: the road to novel therapies for breast cancer
2016
Pancreatic Cancer
2010 Standout
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
2018
Clonal evolution in cancer
2012 StandoutNature
The PI3K Pathway in Human Disease
2017 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Genes that mediate breast cancer metastasis to lung
2005 StandoutNature
ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: The Task Force for the management of acute coronary syndromes (ACS) in patients presenting without persistent ST-segment elevation of the European Society of Cardiology (ESC)
2011 Standout
Characterization of dyspnoea in PLATO study patients treated with ticagrelor or clopidogrel and its association with clinical outcomes
2011
Association Between <emph type="ital">BRCA1</emph> and <emph type="ital">BRCA2</emph> Mutations and Survival in Women With Invasive Epithelial Ovarian Cancer
2012
Pancreatic cancer
2011 Standout
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study
2010
Fluorine in Pharmaceutical Industry: Fluorine-Containing Drugs Introduced to the Market in the Last Decade (2001–2011)
2013 Standout
Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
2011
Practical Approach to Triple-Negative Breast Cancer
2017
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications
2001 Standout
Hereditary gynaecological malignancies: advances in screening and treatment
2012
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Molecular Pathways: How Can BRCA-Mutated Tumors Become Resistant to PARP Inhibitors?
2013
Diabetes and Antiplatelet Therapy in Acute Coronary Syndrome
2011
Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies
2010
Repeated observation of breast tumor subtypes in independent gene expression data sets
2003 Standout
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor Versus Clopidogrel in Patients With Stable Coronary Artery Disease
2009
Hypoxia-inducible factor 1-dependent expression of adenosine receptor 2B promotes breast cancer stem cell enrichment
2018 StandoutNobel
Safety and Tolerability of Antiplatelet Therapies for the Secondary Prevention of Atherothrombotic Disease
2009
The platelet P2Y12 receptor for adenosine diphosphate: congenital and drug-induced defects
2010
New Strategies in the Treatment of Ovarian Cancer: Current Clinical Perspectives and Future Potential
2013
Chemotherapy induces enrichment of CD47 + /CD73 + /PDL1 + immune evasive triple-negative breast cancer cells
2018 StandoutNobel
Minimizing the Risks of Anticoagulants and Platelet Inhibitors
2010
Metabolic reprogramming and cancer progression
2020 StandoutScience
Oral Rivaroxaban for the Treatment of Symptomatic Pulmonary Embolism
2012 Standout
Cancer Genome Landscapes
2013 StandoutScience
Clinical Aspects of Platelet Inhibitors and Thrombus Formation
2007
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
Stent Thrombosis With Ticagrelor Versus Clopidogrel in Patients With Acute Coronary Syndromes
2013
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
HIF-1 regulates CD47 expression in breast cancer cells to promote evasion of phagocytosis and maintenance of cancer stem cells
2015 StandoutNobel
Dose Effect of Clopidogrel Reloading in Patients Already on 75-mg Maintenance Dose
2008
Chemotherapy triggers HIF-1–dependent glutathione synthesis and copper chelation that induces the breast cancer stem cell phenotype
2015 StandoutNobel
Hypoxia-inducible factor-dependent signaling between triple-negative breast cancer cells and mesenchymal stem cells promotes macrophage recruitment
2014 StandoutNobel
Clopidogrel Response Variability and Future Therapies
2006
Works of Mark Wickens being referenced
Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
2011
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations inP2RY12, P2RY1,andITGB3
2009
Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin
2006
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
Inhibition of Platelet Aggregation by AZD6140, A Reversible Oral P2Y12Receptor Antagonist, Compared With Clopidogrel in Patients With Acute Coronary Syndromes
2007